Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methamphetamine and ethanol interactions in humans

J Mendelson1, R T Jones, R Upton

  • 1Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco 94143-0984, USA.

Clinical Pharmacology and Therapeutics
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.

Oncogene·2026
Same author

Saddle-back tamarin (Saguinus fuscicollis) reproductive strategies: Evidence from a thirteen-year study of a marked population.

American journal of primatology·2020
Same author

Correction. Locomotor benefits of being a slender and slick sand-swimmer.

The Journal of experimental biology·2015
Same author

Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.

Progress in neuro-psychopharmacology & biological psychiatry·2013
Same author

Human growth hormone: challenge to non-therapeutic and experimental use.

The International journal of risk & safety in medicine·2013
Same author

Ketamine is associated with lower urinary tract signs and symptoms.

Drug and alcohol dependence·2013
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
See all related articles

Combining methamphetamine and ethanol increases cardiac work, potentially leading to adverse cardiovascular effects. This drug combination may be popular due to increased perceived global intoxication.

Area of Science:

  • Pharmacology
  • Toxicology
  • Cardiovascular Science

Background:

  • Methamphetamine and ethanol are frequently co-abused substances.
  • Understanding the combined effects is crucial for public health and clinical interventions.

Purpose of the Study:

  • To investigate the cardiovascular, subjective, and pharmacokinetic interactions of intravenous methamphetamine and oral ethanol.
  • To assess the effects of methamphetamine alone, ethanol alone, and their combination.

Main Methods:

  • Eight participants completed a double-blind, placebo-controlled, within-subject study.
  • Cardiovascular, subjective, and neuropsychological effects were measured over 6 hours.
  • Plasma and urine samples were analyzed for drug concentrations over 48 hours.

Related Experiment Videos

Main Results:

  • The combination increased heart rate and cardiac work (rate pressure product) but decreased systolic blood pressure compared to methamphetamine alone.
  • Subjective effects of ethanol were diminished by methamphetamine, while methamphetamine's subjective effects were unchanged.
  • Ethanol did not significantly alter methamphetamine pharmacokinetics, except for a reduced volume of distribution.

Conclusions:

  • Concurrent methamphetamine and ethanol use increases cardiac workload, posing greater cardiovascular risks than individual use.
  • The combination may enhance perceived intoxication, potentially contributing to its recreational popularity.
  • Clinicians should be aware of the heightened cardiovascular risks associated with this drug combination.